Ergocalciferol (ergocalciferol) (vit. D2) solution oil oral. 0.125% 10 ml.


Manufacturer: Ukraine

For the prevention and treatment of hypovitaminosis D, rickets, as well as bone diseases caused by calcium metabolism disorders (various forms of osteoporosis, osteomalacia), parathyroid gland disorders (tetany), skin and bone tuberculosis, psoriasis, systemic lupus erythematosus (SLE) of the skin and mucous membranes.



Ergocalciferol Storage:

active substance: ergocalciferol (vitamin D2);

1 ml of the drug contains ergocalciferol 1.25 mg, which corresponds to 50,000 IU;

excipient: refined deodorized sunflower oil brand “P”, frozen.

Dosage form.

Oral oil solution.

Main physical and chemical properties: clear oily liquid from light yellow to dark yellow color, without a bitter smell.

Pharmacotherapeutic group.

Preparations of vitamin D and its analogues. ATX code A11C C01.

Pharmacological properties.

Ergocalciferol Pharmacodynamics.

Ergocalciferol (vitamin D2) regulates the metabolism of phosphorus and calcium in the body, promotes their absorption in the intestine by increasing the permeability of its mucous membrane and adequate deposition in bone tissue. The effect of ergocalciferol is enhanced by the simultaneous intake of calcium and phosphorus compounds.

Vitamin D2 belongs to the group of vitamins soluble in oils and is one of the regulators of phosphorus and calcium metabolism. Promotes the absorption of the latter from the intestine, distribution and deposition in the bones during their growth. The specific effect of the vitamin is especially evident in rickets (anti-rickets vitamin).


Orally taken vitamin D is absorbed into the blood in the small intestine, especially well – in its proximal part. With the blood, the vitamin enters the liver cells where it is
with the participation of 25-hydroxylase is hydroxylated with the formation of its transport form, which is delivered by blood in the mitochondria of the kidneys. In the kidneys it is further hydroxylated with lα-hydroxylase, resulting in the formation of a hormonal form of the vitamin. Already this form of vitamin D is transported by blood to target tissues, for example – in the intestinal mucosa, where it initiates the absorption of Ca ++.

Clinical characteristics.

Ergocalciferol Indication.

For the prevention and treatment of hypovitaminosis D, rickets, as well as bone diseases caused by disorders of calcium metabolism (various forms of osteoporosis, osteomalacia), parathyroid dysfunction (tetany), tuberculosis of the skin and bones, psoriasis, systemic lupus erythematosus and mucous membranes.


– Hypersensitivity to the components of the drug;

– hypervitaminosis D;

– active form of pulmonary tuberculosis;

– peptic ulcer of the stomach and duodenum;

– acute and chronic liver and kidney diseases;

– organic diseases of the heart and blood vessels in the stage of decompensation;

– elevated levels of calcium and phosphorus in the blood and urine;

– sarcoidosis;

– urolithiasis.

Interaction with other drugs and other types of interactions.

Concomitant use with calcium salts increases the toxicity of vitamin D2. When prescribed with iodine, the vitamin is oxidized. At simultaneous use with antibiotics (tetracycline, neomycin) disturbance of absorption of ergocalciferol is observed. The combination of the drug with mineral acids leads to its destruction and inactivation.

Thiazide diuretics, drugs that contain Ca2 +, increase the risk of hypercalcaemia, which causes a decrease in tolerance to cardiac glycosides, which leads to a slow elimination of the drug and its accumulation in the body.

Under the influence of barbiturates (including phenobarbital), phenytoin and primidone, the need for ergocalciferol may increase significantly, which is manifested in increased osteomalacia or severity of rickets (due to accelerated metabolism of ergocalciferol in inactive fermentals due to inactive metabolic).

Long-term therapy with concomitant use of antacids containing Al3 + and Mg2 + increases their concentration in the blood and the risk of intoxication (especially in the presence of chronic renal failure). Calcitonin, etidronic and pamidronic acid derivatives, plicamycin, gallium nitrate and glucocorticosteroids reduce the effect. Cholestyramine, colestipol and mineral oils reduce the absorption of fat-soluble vitamins in the digestive tract and require an increase in their dosage.

Rifampicin, isoniazid, antiepileptic drugs, cholestyramine reduce the effectiveness of ergocalciferol.

Use with caution with ketonazole, cytochrome P450 inhibitors.